Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Attain OTW lead

This article was originally published in The Gray Sheet

Executive Summary

Non-U.S. marketing of Model 4193 over-the-wire lead to the left ventricle of the heart for delivery of cardiac resynchronization therapy for moderate-to-severe heart failure is underway. The 4 Fr steroid-eluting device is designed to stabilize electrical performance and facilitate placement through small and medium-sized veins. The lead tip includes a silicone seal that decreases the entry of bodily fluids to the center lumen. The lead is a component of the InSync biventricular pacing system for cardiac resynchronization
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT015522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel